一个患者的自述：
不仅仅是生存，更要生活。
A patient's account: Not just surviving, but living.
Rita是一个来自葡萄牙的乳腺癌患者，她曾一度担心无法看到女儿长大。而如今，她的生活逐渐回归正轨，曾经遥不可及的梦想正成为现实。
Rita is a breast cancer survivor from Portugal who once feared she wouldn't be able to see her daughter grow up. Today, her life is getting back on track, and her dream is becoming a reality.
作为一个母亲，也是一个乳腺癌患者。Rita曾经和女儿在一起过着幸福快乐的生活，但是突如其来的疾病打破这个宁静祥和的家庭。随着时间的推移，病痛不断折磨着Rita。她的消化系统、免疫系统都受到严重影响，甚至她曾一度无法行走超过50米。医院的化疗折磨着她的身体；手术后的伤疤和女儿的难过也对她的心理造成了极大程度的打击。
As a mother, Rita used to live a happy life with her daughter, but breast cancer shattered the peace and tranquility of her family. As time passed, the disease continued to afflict Rita.Her digestive system and immune system were severely damaged, and at one point, she was unable to walk more than 50 metres. The chemotherapy at the hospital took a toll on her body, the scars from surgery, and her daughter's sadness deeply affected her psychologically.但是，她并没有因为身心上的痛苦和折磨而放弃，她决定勇敢面对所有的一切，因为她深爱着自己的女儿，也深爱着自己的生活。经过18次靶向治疗，Rita逐渐感觉身体好了起来。同时，她也通过写日记为自己的心理和情绪找到了出口。这次经历给Rita带了巨大的改变，她意识到自己不能活在焦虑和压力之中。人生不仅仅要生存，更应该好好生活。
Rita的经历只是千千万万乳腺癌患者的缩影。对于她们而言，治疗不仅关乎延长生命，更关乎如何更好地生活。随着乳腺癌发病率的持续上升，这一疾病已成为全球公共健康的重要挑战。在这一背景下，提升治疗手段的创新与可及性，正成为全球医疗体系关注的重点。在这场全球性的努力中，中国生物制药企业也正在积极参与，并逐步展现出越来越重要的作用。
Rita's experience is just one glimpse into the lives of millions of breast cancer patients. For them, treatment is not only about prolonging life but choosing to live better. With the continuous rise in breast cancer incidence, this disease has become a significant public health challenge globally.In this context, improving the innovation and accessibility of treatment methods has become a focal point for global healthcare systems. In this effort, Chinese biopharmaceutical companies are actively participating and playing an increasingly important role.乳腺癌：全球正在面临的挑战
乳腺癌是全球女性健康面临的重大挑战之一。据世界卫生组织（WHO）统计，乳腺癌目前已成为全球女性最常见的癌症，每年新增病例超过200万例，且发病率呈现上升趋势。这一疾病不仅对患者及其家庭造成了沉重的负担，也对全球医疗系统造成了严峻的挑战。
Breast cancer is one of the major challenges to global women's health worldwide. According to the World Health Organization (WHO), breast cancer has now become the most common cancer among women globally, with more than 2 million new cases each year, and the incidence rate is rising. The disease not only poses a heavy burden on patients and their families, but also poses a serious challenge to the global healthcare system.
国产生物药走向国际
在这样的挑战下，中国的生物制药行业迎来了前所未有的发展机遇。近年来，中国医药企业在全球舞台上频频获得认可，彰显出强大的研发能力和质量保障。作为国产生物药企出海的代表之一，复宏汉霖正以其卓越的创新能力和国际化视野，为全球患者带来福音。
复宏汉霖：深耕乳腺癌领域，关爱患者更关注社会
复宏汉霖是一家总部位于上海、面向全球的国际化创新生物制药公司。它在乳腺癌领域深耕多年，有着丰富的经验储备和专利技术，公司在持续构建覆盖疾病全周期的治疗体系。从围手术期到后线治疗，针对不同分子分型提供个性化治疗方案。
Henlius is a global innovative biopharmaceutical company based in Shanghai. The company has been involved in the field of breast cancer for many years, accumulating experience and patent technology. It is continuously building a comprehensive treatment system covering all the stages of the disease. It offers personalized treatment plans for different molecular classifications, from perioperative period to second-line treatment. 除此之外，复宏汉霖积极投身公益事业，秉持“不让一个乳腺癌患者落下”的初衷，既为患者提供切实帮助，也带动社会各界共同关注肿瘤防治事业，助力“健康中国”建设。近年来，公司携手基金会、患者组织等各方机构，在北京、上海、云南、甘肃等多地开展乳腺癌防治公益项目，推动优质医疗资源走向全国各地。
Additionally, Henlius engages in public welfare initiatives with the aim of “leaving no breast cancer patient behind”. It also provides practical support to patients, encouraging society to join in cancer prevention and treatment efforts, and promotes the “Healthy China” initiative.In recent years, the company has partnered with foundations, patient organizations, and various institutions to launch breast cancer prevention and treatment activities in many areas, including Beijing, Shanghai, Yunnan, and Gansu, promoting the distribution of high-quality medical resources around China.其中，“优医相助-乡村医疗关爱公益行”自2020年启动以来，持续为偏远地区居民提供乳腺癌等肿瘤疾病义诊，切实提升基层医疗可及性；2022年推出的“赋时光予生命”——肿瘤患者关爱公益项目，则重点关注肿瘤患者心理健康需求，通过心理关怀和社会支持，帮助患者和家庭重建抗癌信心、走向身心康复。
“中国方案”出海惠及全球医疗
中国生物药企在乳腺癌等领域的全球发展，不仅展示了中国生物制药行业的潜力，也成为中国高端制造产业的一个缩影。复宏汉霖作为中国生物药出海企业之一，它通过持续创新、卓越运营，将优质的治疗方案惠及全球患者。其在国际市场上的成功，也证明了中国生物制药企业具备与国际巨头竞争的实力。这不仅是中国生物药行业的骄傲，更是全球医疗健康领域的福音。
The global development of Chinese biopharmaceutical companies in fields such as breast cancer not only showcases the potential of China's biopharmaceutical industry but also serves as a microcosm of the country's high-end manufacturing sector. As a representative of Chinese biopharmaceutical companies going global, Henlius brings high-quality treatment solutions to patients worldwide with continuous innovation and excellent operations.Its success in the global market proves that Chinese biopharmaceutical companies have the strength to compete with international giants. This is not only a pride of China's biopharmaceutical industry but a blessing for the global healthcare sector.Advertorial
中国日报双语新闻约 6 分钟